Kyverna’s miv-cel meets all primary and secondary endpoints in stiff person syndrome trial
KYTX•Kyverna Therapeutics announced publication of registrational KYSA-8 trial results for miv-cel, which met all primary and secondary endpoints. A single dose improved mobility and disability, and all patients discontinued chronic immunotherapies.
1. Trial results published
Kyverna Therapeutics announced publication in JAMA Neurology of registrational KYSA-8 trial results for miv-cel in stiff person syndrome. The company said a single dose improved mobility and disability, all patients discontinued chronic immunotherapies, and treatment was well tolerated, with no high-grade cytokine release syndrome or neurotoxicity and no cases of immune effector cell-associated hemophagocytic syndrome.
